Motus GI (MOTS) versus Pulse Biosciences (PLSE) Financial Comparison

Motus GI (NASDAQ: MOTS) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.

Valuation and Earnings

This table compares Motus GI and Pulse Biosciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Motus GI $10,000.00 7,115.49 -$13.20 million ($1.28) -3.57
Pulse Biosciences N/A N/A -$25.56 million N/A N/A

Motus GI has higher revenue and earnings than Pulse Biosciences.

Profitability

This table compares Motus GI and Pulse Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Motus GI N/A N/A N/A
Pulse Biosciences N/A -77.03% -70.27%

Analyst Recommendations

This is a summary of recent ratings for Motus GI and Pulse Biosciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Motus GI 0 0 2 0 3.00
Pulse Biosciences 0 0 0 0 N/A

Motus GI presently has a consensus target price of $7.00, suggesting a potential upside of 53.17%. Given Motus GI’s higher possible upside, analysts clearly believe Motus GI is more favorable than Pulse Biosciences.

Insider & Institutional Ownership

0.0% of Motus GI shares are owned by institutional investors. Comparatively, 10.9% of Pulse Biosciences shares are owned by institutional investors. 39.3% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Motus GI beats Pulse Biosciences on 6 of the 8 factors compared between the two stocks.

Motus GI Company Profile

Motus GI Holdings, Inc., a medical technology company, focuses on the development and commercialization of the Pure-Vu System. Its Pure-Vu System is designed to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company's Pure-Vu System improves colonoscopy experience for physicians, patients, and payers by diminishing the dependency on pre-procedural preparations. The company is based in Tirat Carmel, Israel.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc., a clinical-stage medical technology company, develops therapeutic tissue treatment platform based on its proprietary nano-pulse stimulation (NPS) technology. Its NPS is a non-thermal, precise, and focal drug-free tissue treatment technology that initiates cell death within treated tissue used in oncology, dermatology/aesthetics, minimally invasive, and veterinary applications. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was founded in 2014 and is headquartered in Hayward, California.

Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply